May 30, 2018 10:45 AM EDT

PhRMA's new report counts each cancer drug in the US pipeline, which has now swelled to over 1,000 in the clinic

Brittany Meiling

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Revolution’s KRAS drugs appear competitive in several lung cancer settings

Corvus' early-phase atopic dermatitis data prompt stock rally

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges